

- Hardison WG, Grundy SM. Effect of ursodeoxycholate and its taurate conjugate on bile acid synthesis and cholesterol absorption. *Gastroenterology* 87: 130-135, 1984
- Hood K, Gleeson D, Ruppin DC, Dowling RH, and the British Belgian Gallstone Study Group. Can gallstone recurrence be prevented? The British/Belgian post-dissolution trial. *Gastroenterology* 94: 548, 1988
- Kupfer RM, Maudgal DP, Northfield TC. Gallstone dissolution rate during chenotic acid therapy: effect of bedtime administration plus low cholesterol diet. *Digestive Diseases and Sciences* 27: 1025-1029, 1982
- Lanzini A, Jazrawi RP, Kupfer RM, Maudgal DP, Joseph AEA, et al. Gallstone recurrence after medical dissolution: an overestimated threat? *Journal of Hepatology* 3: 241-246, 1986
- Makino I, Hashimoto H, Shinozaki K, Nakagawa S. Dissolution of cholesterol gallstone by ursodeoxycholic acid. *Japanese Journal of Gastroenterology* 72: 690-702, 1975
- Maton PN, Iser JH, Reuben A, Saxton A, Murphy HM, et al. The final outcome of CDCA treatment in 125 patients with radiolucent gallstones: factors influencing efficacy, withdrawal, symptoms and side effects and post-dissolution recurrence. *Medicine* 61: 85-96, 1982
- Maudgal DP, Kupfer RM, Northfield TC. Factors affecting gallstone dissolution rate during chenotic acid therapy. *Gut* 24: 7-10, 1983
- Mok HYI, Bell GD, Dowling RH. Effect of different doses of chenodeoxycholic acid on bile lipid composition and frequency of side effects in patients with gallstones. *Lancet* 2: 253-257, 1974
- Newman HF, Northrop JD. The autopsy incidence of gallstones. *International Abstracts in Surgery* 109: 1-13, 1959
- Northfield TC, Lanzini A, Jazrawi R, Maudgal DP, Kupfer RM. Methods for improving the efficacy of litholytic therapy. In Paumgartner et al. (Eds) *Enterohepatic circulation of bile acids and sterol metabolism*, pp. 335-350, MTP Press, Lancaster, 1985
- Roda E, Bazzoli F, Labate AMN, Mazzella G, Roda A, et al. Ursodeoxycholic acid vs chenodeoxycholic acid as cholesterol gallstone dissolving agent: a comparative study. *Hepatology* 2: 804-810, 1982
- Ruppin DC, Dowling RH. Is recurrence inevitable after gallstone dissolution by bile acid treatment? *Lancet* 1: 181-185, 1982
- Salen G, Nicolau G, Shefer S. Chenodeoxycholic acid inhibits elevated hepatic HMG-CoA reductase activity in subjects with gallstones. *Clinical Research* 21: 523, 1973
- Sauerbruch T, Delius M, Paumgartner G, Holl J, Wess O, et al. Fragmentation of gallstones by extra-corporeal shock waves. *New England Journal of Medicine* 3314: 818-822, 1986
- Schoenfield LJ, Lachin JM, the Steering Committee and the National Co-operative Gallstone Study Group. Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the national co-operative gallstone study. *Annals of Internal Medicine* 95: 257-282, 1981
- Thistle JL, May GR, Bender CE, Williams HJ, Le Roy AJ, et al. Dissolution of cholesterol gallbladder stones by methyl tert-butyl ether administered by percutaneous transhepatic catheter. *New England Journal of Medicine* 320: 633-639, 1989
- Toulet J, Rousselet J, Viteau JM, Duchon Y, Pagniez R, et al. Récidives et prévention des récidives après dissolution de la lithiases vésiculaire par l'acide chéno-désoxycholique chez 22 patients. *Gastroentérologie Clinique et Biologique* 7: 605-609, 1983
- Ward A, Brogden RN, Heel RC, Speight TM, Avery GS. Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy. *Drugs* 27: 95-131, 1984
- Wolpers C. Morphologie der gallsteine. *Leber Magen Darm* 4: 43-57, 1974

Correspondence and reprints: Prof. T.C. Northfield, Division of Biochemical Medicine, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, England.

Errata

Vol. 40, No. 3, 1990: Some inconsistencies in the literature regarding ketotifen plasma concentrations have been incorporated into our review and the following corrections are required:

- Page 414:** The units for C_{max} and AUC quoted in lines 5 to 7 of the Pharmacokinetic Properties section should read $\mu\text{g/L}$, $\mu\text{g/L} \cdot h$ rather than mg/L and $\text{mg/L} \cdot h$, respectively.
- Page 423/424:** Since the concentration of 1 mg/L is supratherapeutic, the comment included in parentheses in the final sentence ('i.e. an achievable plasma concentration') on page 423 is no longer applicable and should be deleted.
- Page 427:** The values 1.92 mg/L and 16.98 mg/L in lines 5 and 6 of the right hand column should read 1.92 $\mu\text{g/L}$ and 16.98 $\mu\text{g/L}$, respectively.
- Page 428:** The units mg/L and $\text{mg/L} \cdot h$ in lines 9 and 12 of the left hand column should read $\mu\text{g/L}$ and $\mu\text{g/L} \cdot h$, respectively.
- Page 429:** The plasma concentration units of mg/L in fig. 6 should read $\mu\text{g/L}$.

Vol. 40, Suppl. 3, 1990: In the Round-Table Discussion on page 131, Dr R.K. Chawla's response to a question about the effect of SAME on symptoms of schizophrenia included observations by Fazio et al. (1973). This study involved 49 depressed inpatients and 3 schizophrenics, not 49 schizophrenic patients as stated. The study reported 'positive results in over 80% of cases of depressed patients and changes in psychomotor hyperactivity in the schizophrenics'.

Vol. 41, No. 1, 1991: The first sentence of the Synopsis should read 'Bopindolol is a nonselective β -adrenoceptor antagonist with partial agonist activity...'